Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership

In a recent interview with Applied Clinical Trials, Paul Shawah, EVP of Strategy at Veeva Systems, and Richard Staub, President of R&D Solutions at IQVIA, discussed their companies’ new global clinical and commercial partnership. Designed to simplify and accelerate clinical trials, the collaboration aims to maximize value for customers by integrating software, data, and services from both organizations. Early feedback has been overwhelmingly positive, underscoring the partnership’s potential to streamline workflows, enhance data quality, and support both traditional and decentralized clinical trial models, ultimately helping sponsors bring therapies to market faster.

ACT: How does the partnership enhance clinical data management capabilities for companies running global trials?

Staub: The industry has long recognized IQVIA as a leader in data management, whether it’s EDC build strategies, data cleaning approaches, or rapidly locking databases. Leveraging the Veeva EDC system adds another “arrow to our quiver.” Our goal is to bring the best technologies to our customers, and Veeva’s Vault platform represents a significant advancement in clinical research. They’ve made tremendous progress over the past few years, and we felt it was important to integrate these systems, combining their technology with our services in a way that delivers real value to customers.

Shawah: I’d add that this partnership brings together IQVIA’s expertise and leadership in the CRO space with new collaborative potential. Previously, we didn’t focus much on partnering, so we weren’t fully exploring what it could deliver. Now, we can unlock that potential. We’ll start by doing the basics exceptionally well, but over time, this partnership could drive innovations we haven’t even imagined yet.

Full Interview Summary: IQVIA and Veeva have launched a new global clinical and commercial partnership aimed at simplifying and accelerating clinical trials while maximizing value for customers. The primary goal of the collaboration is customer success—enabling clients to seamlessly access and use software, data, and services from both companies in an efficient, integrated manner. Early feedback on the partnership has been overwhelmingly positive, highlighting its potential to deliver both near-term and long-term benefits.

On the commercial side, the agreement allows customers to combine technologies from IQVIA and Veeva easily. IQVIA has joined Veeva’s technology and services partner programs as an AI partner, opening opportunities for its data to enhance Veeva products, including AI-driven applications. Clinically, IQVIA can leverage Veeva’s full suite of applications, such as Veeva EDC, to streamline study builds and trial execution. By combining the strengths of both organizations, the partnership aims to simplify workflows, improve compliance, and speed up data collection and cleaning, enabling sponsors to bring therapies to market faster.

The collaboration enhances clinical data management by integrating IQVIA’s CRO expertise with Veeva’s technology platforms. This “plug-and-play” approach allows trial sponsors to use the best-fit technologies for each study, improving efficiency and data quality. Sites benefit from user-friendly systems that encourage timely data entry, while sponsors gain faster access to clean, locked data for regulatory submission or progression to the next development phase.

Looking ahead, the partnership is positioned to support decentralized and hybrid trials, where technology interfaces directly with patients in addition to traditional sites. By combining operational expertise with advanced technology, IQVIA and Veeva aim to enable flexible, patient-centric studies that reduce timelines, improve research efficiency, and create new opportunities for innovation in clinical trial design.